705例神经内科问题医嘱的帕累托图分析

doi:10.19803/j.1672-8629.2022.08.17

摘要/Abstract

摘要： 目的临床药师通过医嘱前置审核,对神经内科705例问题医嘱进行帕累托图分析,为临床提供参考。方法对我院神经内科2017年3月1日至2018年2月28日住院的所有患者医嘱前置审核,对发现的问题医嘱进行干预,记录问题医嘱的类型、潜在风险的严重程度、干预的结果进行统计分析。结果共审核811例患者医嘱10 367条,发现问题医嘱705条,包括给药方法511例,适应证不适宜66例,给药剂量不足或过大46例。按照问题医嘱严重程度,较低几率引起药品不良事件（ADE）的I类538例（76.31%）,有一定几率引起轻微ADE的II类135例（19.15%）,有较高几率引起ADE的III类26例（3.69%）,可能引起严重的ADE的IV类6例（0.85%）。医师接受药师建议的541例（76.74%）。结论神经内科住院患者用药品种多而复杂,易出现不适宜的用药医嘱,临床药师进行医嘱审核有助于发现潜在的用药风险,医师对药师建议基本能够接受,两者合作更能够提高患者用药的安全。

关键词: 神经内科, 临床药师, 医嘱前置审核, 问题医嘱

Abstract: Objective To conduct a Pareto chart analysis of 705 problematic prescriptions by clinicians in the Department of Neurology in order to provide reference for clinical practice. Methods Prescriptions pre-audited in the Department of Neurology between March 1, 2017 and February 31, 2018 were collected and analyzed. The types of problems, potential risks and results of interventions were recorded. Results A total pf 10 367 prescriptions for 811 patients were reviewed, 705 of which were found to be problematic, including 511 cases of inappropriate medication methods, 66 cases of wrong indications, and 46 cases of insufficient or excessive dosage. In terms of severity, 538 cases (76.31%) were classified as Class I with a low risk of adverse drug events (ADE), 135 cases (19.15%) as Class II with a medium risk of ADE, 26 cases (3.69%) as Class III with much chance of ADE, and 6 cases (0.85%) as class IV that might cause serious ADE. Physicians took the advice of pharmacists in 541 of these cases (76.74%). Conclusion There are various medications for inpatients in a neurology department, so inappropriate medication instructions are likely. Pre-audition of prescriptions by clinical pharmacists can help identify potential risks of medication. Cooperation between physicians and pharmacists can improve the medication safety of patients.

Key words: neurology, clinical pharmacist, pre-audition of medication instructions, problematic prescriptions

中图分类号:

R994.11
R971

卫红涛, 沈素, 李丹丹, 廖音. 705例神经内科问题医嘱的帕累托图分析[J]. 中国药物警戒, 2022, 19(8): 900-903.

WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin. Pareto chart analysis of 705 problematic prescriptions in neurology[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903.

参考文献

[1] XUE GZ.China Health Statistics Yearbook[M]. Bengjing: China Union Medical University Press, Beijing: 2018.
[2] HONG TW, LA L, SHENG C, et al.A randomized controlled trialon effect of drug education by clinical pharmacists on secondary prevention and compliance of stroke patients[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(4): 399-402.
[3] PETRINI E, CAVIGLIA GP, PELLICANO R, et al.Risk of drug interactions and prescription appropriateness in elderly patients[J]. Ir J Med Sci, 2020, 189(3): 953-959.
[4] XIAO YX, JIAN P.The present situation of the treatment of coronary artery disease in our country is not rational drug use and countermeasures[J]. Chinese Journal of Cancer Prevention and Treatment(中华肿瘤防治杂志), 2016, 23(S1): 261-262.
[5] FENG L.Analysis of current situation and countermeasures of clinical irrational drug use[J]. China Health Industry(中国卫生产业), 2012, 9(3): 132.
[6] JING L, JIAN CZ.Analysis of inpatient medical prescriptions of oral medicines between 2013 and 2016[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(2): 113-115, 118.
[7] Ministry of Health, State Administration of Traditional Chinese Medicine, General Logistics Department, Ministry of Health. Notice on Printing and Distributing the "Regulations on the Administration of Pharmaceutical Affairs in Medical Institutions"[EB/OL].(2011-04-07)[2021-05-01]. http://www.nhc.gov.cn/yzygj/s3593/201103/4119b5de252d45ac916d420e0d30fda7.shtml.
[8] YI ZM, SUN SS, LI XX, et al.An evaluation of clinical pharmacist service on a neurology care unit[J]. Int J Clin Pharm, 2016, 38(1): 30-33.
[9] TAEGTMEYER AB, CURKOVIC I, CORTI N, et al.Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients[J].Swiss Med Wkly, 2012, 142: w13615.
[10] HONG TW, SU S, DANDAN L, et al.Clinical evaluation of lowering the morbidity of cerebrovascular disease and the plasma cysteine levels by b group vitamins based on meta-analysis[J]. China Pharmacist(中国药师), 2017, 20(11): 2004-2008.
[11] PENG ZH, DAI HG, WANG PJ, et al.Intelligentialized real-time surveillance study on adverse drug reactions caused by cinepazide maleate[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2018, 15(2): 92-95.
[12] XIAO JZ, QIAO RZ.Clinical effect and adverse reactions of vinpocetine in the treatment of acute coronary syndrome with hypertension[J]. Prevention and Treatment of Cardiovascular Disease(心血管病防治知识), 2018(14): 26-28.
[13] SHENG C, JUN XY, HONG TW, et al.Evaluation of the rationality and safety of clinical application of fasudil hydrochloride injection[J]. China Pharmacist(中国药师), 2019, 22(8): 1474-1476.
[14] PENG XG, PENG FL, LI D, et al.Effect of omeprazole on pharmacodynamics of clopidogrel[J]. Carcinogenesis, Teratogenesis & Mutagenesis(癌变•畸变•突变), 2015, 27(6): 477-479.
[15] JUN C, HUAI JZ, LI N, et al.Quantitative analysis of drug interaction between paroxetine and metoprolol based on linear mixed model[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(20): 2054-2058.
[16] HAI XZ, JUN M, LAN Y, et al.Clinical analysis of meropenem reducing plasma concentration of valproate acid in patients[J]. China Pharmacist(中国药师), 2019, 22(11): 2070-2073.
[17] YING Y, DONG LL, FEI C, et al.Pareto diagram analysis of intervention in irrational medical orders for inpatients of endocrinology[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 921-925, 933.
[18] ZENG ZZ, GANG L, JING Z, et al.Intervention and analysis of 1860 cases of irrational drug use for inpatients by clinical pharmacists[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(13): 1237-1239.
[19] BO Y, JING T. Investigation on the effect of clinical pharmacist educating on doctors and nurses[J]. Beijing Medical Journal(北京医学), 2017, 39(3): 265, 270.
[20] TAO R, YING YC, JIAN PH, et al.Survey on pharmacological knowledge of asthma in physicians[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2003, 22(7): 426-429.
[21] XU Y.Application of fasudil hydrochloride in patients with acute cerebral infarction and its effect on vascular endothelial growth factor[J]. Chinese Journal of Practical Nervous Diseases(中国实用神经疾病杂志), 2019, 22(4): 380-385.
[22] YI C.Clinical effect of fasudil on acute ischemic stroke[J]. Journal of North Pharmacy(北方药学), 2019, 16(2): 101-102.